Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

NCT06977594 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

1000

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Endometrial Cancer
Cervical Cancer

Interventions

OTHER: Proactive immune tolerance induction
OTHER: Standard Treatment
DRUG: Paclitaxel and carboplatin
DRUG: Standard premedication (20 mg)
DRUG: Reduced premedication (10 mg)
DRUG: Reduced premedication (5 mg)

Sponsor

Seoul National University Hospital

Collaborators

[object Object]
[object Object]
[object Object]